This effect was blunted when chemotherapy was combined with M-CSFR blockade, resulting in increased anti-tumor CD8+ T-cell responses and improved inhibition of tumor growth and metastasis as compared to chemotherapy as monotherapy. The gene discussed is CD8A; the disease is neoplasm.